Subscribe
yanlev-shutterstock-com-1
YanLev / Shutterstock.com
3 December 2015AmericasGerard Norton and Michael Montgomery

To dance or not to dance: biosimilar strategies post Amgen v Sandoz

The Biologics Price Competition and Innovation Act (BPCIA) is a landmark piece of legislation signed into law by the Obama administration in 2009. The BPCIA provides for a regulatory approval pathway for biosimilar products, which are like generic pharmaceuticals in that they are based on already approved ‘name brand’ biologics.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
US approves second biosimilar drug
6 April 2016   The US Food and Drug Administration has approved a biosimilar version of Janssen Biotech’s drug Remicade.
Americas
Apotex ordered to provide 180 days’ biosimilar notice to Amgen
15 December 2015   Parties are required to provide 180 days’ notice to a patent owner before marketing a biosimilar version of its drug, a US district court has ruled.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
US approves second biosimilar drug
6 April 2016   The US Food and Drug Administration has approved a biosimilar version of Janssen Biotech’s drug Remicade.
Americas
Apotex ordered to provide 180 days’ biosimilar notice to Amgen
15 December 2015   Parties are required to provide 180 days’ notice to a patent owner before marketing a biosimilar version of its drug, a US district court has ruled.

More on this story

Americas
US approves second biosimilar drug
6 April 2016   The US Food and Drug Administration has approved a biosimilar version of Janssen Biotech’s drug Remicade.
Americas
Apotex ordered to provide 180 days’ biosimilar notice to Amgen
15 December 2015   Parties are required to provide 180 days’ notice to a patent owner before marketing a biosimilar version of its drug, a US district court has ruled.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
LSPN: Counsel grapple with AI’s impact on training and critical thinking
LSPN: Trump's policy storm causing chaos and confusion
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB
Novartis settles with licensee of blood cancer therapy day before trial
Foley adds five-partner team from Perkins Coie and K&L Gates
UPC orders 17-country ban on EOFlow's pumps in Insulet feud